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Background: A rapid development of viral drug resistance poses a serious
limitation in the current drug development programs against HIV. In turn, this
obstacle forms the basis for new efforts, which utilize alternative viral targets.
Results: By aiming at the Tat-driven process of HIV gene regulation, we
discovered a new class of compounds as well as a novel target. The candidate
compound acts on the one hand by classically inhibiting Tat/TAR complexation,
however, without binding to nucleic acids.
Conclusions: Structure and molecular modeling/dynamics suggest that the
stilbene derivative CGA137053 directly binds to Tat protein but not TAR RNA. As
a completely new, second property, the compound also antagonizes a TAR-
independent activity of free Tat protein by preventing the recently described
upregulation of the HIV coreceptor CXCR4. With the stilbene CGA137053, we
have identi¢ed a potent, double-hitting and chemically feasible Tat antagonist.
The compound possesses high target speci¢city and low cytotoxicity, is not
restricted to the Tat/TAR axis of HIV inhibition and highly active on HIV-infected,
primary human cells.
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Introduction
The majority of therapeutically active chemicals target pro-
teins, such as receptors or enzymes. Although a number of
drugs targeting nucleic acids have been known, e.g. in the
chemotherapy of cancer, only few attempts have been re-
ported which directly target the interaction of a protein
with a speci¢c nucleic acid. With the rapid increase of
knowledge about genes involved in establishment, pro-
gression or control of diseases, this new concept for ther-
apeutic intervention is beginning to raise pharmaceutical
interest. Successful examples have recently been described
[1], which interfere with HIV-1 replication through a block
of viral transcription. Speci¢c disruption of protein/nucleic
acid interactions, occurring directly on the viral long termi-
nal repeat (LTR), was achieved using synthetic molecules.
The interaction of cellular transcription factors with cis-
DNA elements was blocked through the use of polyamide
molecules designed to recognize and bind to the minor
groove of those short DNA sequences [1]. Similarly, other
studies reported de novo designed substances that were
binding to the viral TAR element (Tat-responsive RNA),
and prevented complex formation with the transactivator
Tat thereby blocking HIV replication [2^4]. In both ap-
proaches, the described compounds bound the nucleic
acid partner of the complex. Pharmaceutically, a nucleic
acid target is highly delicate with respect to selectivity
and reversibility of binding, and e.g. cancer chemotherapy,
often utilizing DNA-binding agents, provides examples of
deleterious side effects (mutagenicity, severe toxicity, etc.).
One way of circumventing this drawback is to consider the
facing partner of such a ‘molecular tango’. Indeed, in the
molecular recognition process between the nucleic acid-
binding site of a protein and the protein-binding region
of a nucleic acid, each can be seen as ‘receptor’ or ‘ligand’.
The ¢nding of small molecular weight inhibitors should
therefore not be restricted to one or the other. Corollary,
appropriate assay design should allow identi¢cation of both
types of molecules. Accordingly, a random screen, de-
signed for a search of inhibitors of the Tat/TAR interaction
in vitro, led to the discovery of a new class of potent
compounds, which interestingly have no af¢nity for TAR
RNA.
Results
In vitro competition of Tat/TAR complex formation
The high throughput screen (F.H. and T.K., manuscript in
preparation) identi¢ed a peculiar, structurally related series
of compounds. Brie£y, in this assay, a biotinylated TAR-
binding peptoid (described in Hamy et al. [2]), bound to
streptavidin plates, was reacted with Eu-labelled TAR
RNA. This interaction was competed by the respective
compounds, and decrease of bound Eu label was scored.
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The most active compound of the identi¢ed class was
CGA137053 (Figure 1). As a remarkable feature, this struc-
ture does not have apparent homology with any of the
previously reported Tat/TAR inhibitors [2^4]. The most
striking difference to cationic RNA-binding inhibitors was
that CGA137053 is negatively charged at physiological pH
through the presence of two sulfonate groups
(pKa1 =30.83; pKa2 =31.57). In the screening effort of
the corporate library (s 200 000 entities, hit-rate of
0.02%), the vast majority of compounds was inactive, pro-
viding an easy starting point for the identi¢cation of appro-
priate negative controls. As shown in Figure 1, ba12330
re£ects the one structurally closest to the active substance.
This compound pair was ¢rst pro¢led for inhibition of Tat/
TAR complex formation by competition electromobility
shift assay (EMSA). In this assay format, the amount of
recombinant Tat protein was adjusted to shift 50% of the
radiolabelled TAR (Figure 2a, lane ‘3Tat’) into a complex,
visible as gel-retarded form (Figure 2a, lane ‘0’). Increasing
amounts of inhibitor (as indicated) were then added to this
pre-formed complex and subjected to electrophoresis. As
can be estimated from the autoradiograph in Figure 2a,
CGA137053 was active with a CD50 (concentration of com-
pound required for decreasing the retarded complex by
half) in the low nanomolar range. The concentration range
was found to be close to stoichiometric with the input
amount of the reaction partners Tat (20 nM) and TAR
(12.5 nM). In contrast, the CD50 value of ba12330 was at
least 40-fold higher. It is also interesting to note from the
autoradiographs that compound inhibition did not coincide
with a detectable ‘direct shift’, which would have been an
indicator for a direct contact between compound and TAR
RNA. This phenomenon, attributed to a change of confor-
mation of RNA upon drug-binding, was usually quite ap-
parent for previously pro¢led TAR binders [2^4]. Using
also other methodologies, no direct RNA-binding could
be detected (RNase A foot-printing or measurements of
differential melting temperature, data not shown).
Our experimental setup involved only three reaction part-
ners: puri¢ed recombinant Tat, synthetic TAR and the
respective compound. Such an assay simplicity prompted
us to further investigate the hypothesis that the negatively
charged compounds could indeed interact with Tat.
Dynamics of Tat/TAR inhibition
These preliminary clues towards Tat-binding of the com-
pound led us to investigate whether the order of addition
of reactants would have an in£uence on the experimental
outcome. For this, two of the three reaction partners (i.e.
Tat plus inhibitor or TAR plus inhibitor) were premixed
and incubated prior to the addition of the third (Figure 2b).
Non-denaturing electrophoresis was performed immedi-
ately before the binding reaction had reached equilibrium
(5 min at 0‡C). A remarkable difference between the two
conditions was observed: preincubation of Tat protein plus
compound (Figure 2b, right-hand side) was s 10-fold more
potent in blocking Tat/TAR complex formation than when
compound was added after Tat/TAR complexation (Figure
2b, lanes on the left). In summary, compound concentra-
tions as low as 3 nM abrogated the ability of Tat to form a
complex with TAR.
Tat antagonism inside cells
Inhibition of Tat transactivation in cells
In order to prove that disruption of the Tat/TAR complex
can translate into a speci¢c inhibition of Tat-driven trans-
activation even inside the intact cell, a standard reporter
cell assay [5] was performed. Brie£y, in this stable LTR
activation cell system (SX22-1 cells), native Tat protein is
introduced via cocultivation with the constitutively HIV-1
producing lymphocyte line (Hut/4-3). The setup relies
upon gp120/CD4-mediated virus entry. The HIV typical
membrane fusion leads to the generation of giant, multi-
nucleated fusion products (syncytia), which readily stain
blue with 5-bromo-4-chloro-3-indolyl L-D-galactoside (X-
Gal) only in the presence of effective LTR transactivation
by Tat. Hence it strictly depends on the Tat/TAR inter-
action. The active compound CGA137053 induced white
syncytia, demonstrating Env-mediated cell fusion but no
LTR activation, as depicted in Figure 3b. The presence of
extended syncytia was also a direct proof that the inhibitors
did not act at the fusion level as generally seen for anionic
entities [5] (oligonucleotides, dextran sulfate, etc.). In con-
trast, the control compound ba12330 did not have any
Figure 1. Structures of sulfonated stilbene compounds found to
possess potent activity against HIV Tat (CGA137053) or to serve
as related negative control (ba12330).
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in£uence on L-galactosidase (L-Gal) induction (Figure 3a),
and blue syncytia indicate that cell fusion was unaffected.
Figure 3c shows a graphical representation of the quanti-
¢ed LTR activity through the L-Gal-mediated conversion
of ortho-nitro-phenyl-galactopyranoside (ONPG) to ortho-
nitro-phenol (ONP) (described in Klimkait et al. [5]).
Already at 3 WM concentration of CGA137053, a signi¢cant
reduction of LTR activity was consistently observed, and
at 10 WM more than 95% of the Tat activity was inhibited,
proving that the compound had readily entered the cell.
The control compound ba12330 showed no Tat-inhibitory
activity. It is noteworthy that even at 100 WM none of the
compounds showed any sign of cytotoxicity in the cell
lines tested (not shown).
To further address the compound’s speci¢city and cell en-
try, we analyzed HIV-inhibitory activity also following
DNA transfection into SX22-1 cells of either the complete
proviral clone pNL4-3 (Figure 3d, left panel) or the Tat
expression plasmid pTat/Rev (Figure 3d, right panel). By
microscopic inspection of blue events (not shown) and en-
zymatic quanti¢cation, Tat-speci¢c inhibition was observed
only with CGA137053, but no activity was seen with the
ba12330 control (Figure 3d). When a constitutively active
CMV-lacZ plasmid was transfected, no inhibition was ob-
served with either compound up to the highest tested
concentration of 30 WM. Moreover, also trans-regulated re-
porters such as androgen- or estrogen-responsive constructs
(ARE-luc, ERE-tk-luc) remained unaffected by the stil-
benes (not shown).
These cellular experiments match the biochemical data of
activity and selectivity; they further demonstrated that
CGA137053 can speci¢cally block complex formation of
Tat and TAR intracellularly and subsequently prevent
HIV-1 gene activation.
Antagonism of free Tat protein
In addition to an infection-associated activity of Tat, a role
of free Tat protein has been implicated in HIV-induced
pathogenesis. Some of these extra activities have recently
been characterized (reviewed in Gallo [6]), one of them in
the induction of CXCR4 coreceptor expression [7]. We
chose reverse transcriptase (RT)-PCR to probe for a possi-
ble antagonism also of this function of Tat. As shown in
Figure 4, CXCR4 mRNA becomes readily detectable in
fresh, unstimulated human peripheral blood lymphocytes
(PBLs) after the exposure to recombinant Tat protein (100
ng/ml) (lane 2), or after stimulation with phytohemaggluti-
nin (PHA) (1%) (not shown). The Tat-driven induction is
suppressed by the addition of e.g. 10 WM CGA137053
(lane 3) but not with ba12330 at the same concentration
(lane 4). Tat speci¢city of this inhibition is supported by
the observation that PHA-stimulated CXCR4 expression
was not affected by CGA137053 (lane 5). In addition, the
endogenous RNA levels for L-actin remained constant
even when Tat or PHA were added, irrespective of the
presence of either stilbene (not shown).
Inhibition of HIV replication
In order to test whether the Tat antagonistic activity could
further be extended to blocking viral replication in clini-
cally relevant cells, we performed HIV-1 infection experi-
ments of human PBLs from healthy donors. Figure 5a
shows the graphical representation of viral replication pro-
¢les, which can be measured as HIV-speci¢c RT activity in
the culture supernatant, since this viral enzyme is strictly
particle-associated. Again, CGA137053 clearly showed a
dose-dependent inhibition of HIV-1 replication, and 30
WM achieved fully suppressive activity (Figure 5b). In in
vitro differentiated macrophages, another clinically highly
relevant infection system, again a dose-dependent inhibi-
tion was observed with suppression of s 95% at 30 WM
Figure 2. In vitro inhibition of Tat/TAR complex formation.
(a) Radiograph of an EMSA with 32P-labelled TAR and
recombinant Tat in the presence of compound concentrations in
nM as indicated. Lane `3Tat' indicates control lane without
compound. (b) Dynamics of Tat/TAR complex formation. Mobility
shift assay of Tat and TAT with or without CGA137053: `order of
addition' experiment in which the reaction partners are combined
in the order as depicted above the graph (described in the text).
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concentrations of CGA137053 19 days after infection (Fig-
ure 5a). This block of viral replication was reproduced with
various HIV-1 and even HIV-2 or SIV strains (HIV-
1IIIB; MN; RF; EHO, HIV-2ROD, SIVmac251) with EC90 ranging
from 0.5 to 5 WM (details to be published elsewhere). The
ba12330 control was inactive at 30 WM in all infection
systems; the possibility that the compounds could have a
direct impact on the assay read out was ruled out by adding
the substances directly to the RT test itself (not shown).
Discussion
The compound CGA137053, identi¢ed by high throughput
screening, showed to be highly potent in competing with
Tat/TAR complex formation in vitro. The observed active
concentration suggests that it occurs close to a 1:1 molar
ratio of Tat or TAR in the reaction. This can be explained
by the Kd for the compound towards its recognition partner
(Tat) to be below the Kd of the authentic partner (TAR).
Such an af¢nity was never observed for compounds that
we had previously reported as strong and sequence-speci¢c
TAR binders [2^4].
Our ¢ndings regarding the dynamics of Tat/TAR inhibition
in vitro show that activity of CGA137053 was enhanced by
more than 10-fold when protein and compound were pre-
incubated before an equilibrium with TAR RNA had oc-
curred. This ¢nding was further corroborated by the fact
that several classical methods to assess TAR-binding inhib-
itors, such as melting temperature or linear dichroism or
RNase A foot-printing, failed to show direct interaction of
the compound with RNA (not shown). Thus the simplest
explanation to the observed inhibitory pro¢le of the com-
pound is the unique ¢nding of a direct (TAR-mimicking)
interaction with Tat protein.
Figure 3. Cellular anti-Tat activity of CGA137053 and ba12330. Panel (a) depicts the coculture of indicator plus HIV cells in the presence
of 10 WM control compound ba12330 with numerous blue syncytia. Panel (b) shows the parallel culture treated with CGA137053 at 10 WM
¢nal concentration. Extended white syncytia are indicated by arrows. Panel (c), the ONP-reading of cells cultured in ascending
concentrations (0^30 WM) of the compounds: (b), CGA137053; (F), ba12330. Panel (d), demonstration of Tat effect from `within' cells.
Indicator cells were transfected with DNA of either the complete proviral HIV-1 clone pNL4-3 or the Tat plasmid pTat/Rev as indicated.
Graphs depict Tat-mediated LTR induction (relative L-Gal activity) as a function of compound concentration (0^30 WM): (R), CGA137053;
(a), ba12330.
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Although the small series of related compounds available is
undoubtedly too limited to allow speci¢c conclusions about
a structure/activity relationship, we analyzed for possible
hallmarks in the structure of the compounds that could
help to explain the observed activity. Active compound
CGA137053 (Figure 1) can be de¢ned as a di-sulfonated
stilbene moiety linked to a pyrrazole ring on one side and
to a mono-substituted amine on the other side. Substruc-
ture searches of the corporate compound library revealed
that alterations in either one of the two negative charges or
in the spacing between them yielded inactive compounds.
The same was observed for substitutions of the pyrrazole
moiety. Therefore (and prior to the availability of a com-
prehensive SAR analysis), we generated a speculative
‘model’, which provides the simplest explanation for our
¢ndings. As one important feature for molecular recogni-
tion is often contributed by electrostatic interactions, we
¢rst propose the two negative charges of the sulfonate
groups and the strong nucleophilic pyrrazolic nitrogen to
be candidates for the constitution of an electrostatic phar-
macophore. A Monte Carlo search for a minimal energy
conformation on CGA137053 yielded the structure de-
picted in Figure 6b. Distances and angles between the
three atomic groups of the above-de¢ned pharmacophore
are summarized in Figure 6. As experimental data sug-
gested that the compound mimics TAR RNA for the bind-
ing to Tat, we scrutinized the available three-dimensional
structures of (arginine-bound) TAR to identify character-
istics possibly matching the suggested pharmacophore.
Figure 6a depicts the three-dimensional representation of
the bulge region de¢ning the Tat-binding site of TAR
RNA, as published by Aboul-Ela et al. [8]. In this model,
atomic groups previously reported as central actors of the
Tat/TAR interaction [9,10] are highlighted: the heterocy-
clic N7 of guanine G26 and phosphate groups in the nu-
cleic backbone of the unpaired residues. Distances and
angles between these atomic groups were measured and
averaged from the 20 different structures determined by
nuclear magnetic resonance. We could ¢nd that nature and
geometry of these could be precisely mimicked by distinct
groups within CGA137053 with matching spatial display
and electrostatic characteristics. This allowed us to specu-
late that (i) the nucleophilic/H-bond acceptor N7 (shown
to interact with the guanido group of an arginine residue of
Tat [8,10]) could be advantageously mimicked by the even
more nucleophilic nitrogen of the OH-pyrrazole moiety,
and (ii) the two sulfonate groups could possibly mimic
phosphates of the RNA backbone (possibly P25 and P26,
shown in Figure 6a). As the RNA-binding region of Tat
Figure 5. Antiviral activity of CGA137053
in primary human leukocytes (PBL) (a) and
macrophages (b). After viral adsorption,
compound was added to the infected
cultures at the following concentrations:
untreated control (a), 3 WM (F), 10 WM (R)
and 30 WM (8). Supernatant RT activity as
a function of time post infection was
determined at the indicated time points.
Figure 4. Inhibitory activity on Tat-mediated CXCR4 gene
expression. RT-PCR was performed on mRNA from unstimulated
PBLs in the absence of Tat and compound (lane `0'), in presence
of 100 ng/ml Tat or 1% PHA and/or 10 WM compounds as
indicated. `M' indicates size marker lane.
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has been previously reported to have a certain degree of
£exibility [11], we suggest that our class of compounds is
readily recognized by Tat protein which is then titrated out
of its interaction with TAR RNA. As a further extension to
our hypothesis, the explanation why ba12330 is not active
could possibly come from the presence of a primary amine,
which may con£ict in the interaction with the basic, Arg-
rich TAR-binding domain of Tat.
Compounds with negative charges (e.g. sulfonated/phos-
phonated distamycin conjugates) have been reported to
inhibit HIV replication in primary cells as well as LTR
activation [12] in cellular settings similar to ours. These
molecules had at that time been postulated to mainly act
at the fusion level. Unfortunately, no data on any direct in
vitro inhibition of Tat/TAR complex formation were re-
ported. Our assays clearly demonstrate that the compounds
described here act at the Tat/TAR level in a way which is
distinct from an effect on fusion. Furthermore, we com-
pared dextran sulfate, which shows a completely different
activity pro¢le in our assays in that we could not show any
in vitro inhibition of Tat/TAR-binding, but consistently
¢nd a predominant effect on fusion (not shown). In turn
we do not exclude that our compounds may have an addi-
tional bene¢cial activity outside the cell. Indeed, Tat has
been demonstrated to possess diverse activities on cells,
which do not involve the recognition of TAR (reviewed
by Gallo [6]). Among other activities, extracellular Tat,
possibly secreted from infected cells or released from cel-
lular debris of disintegrating cells, has been discussed to
promote HIV infection through an induction of HIV co-
receptor expression, such as CXCR4 or CCR5 [7]. Since
the population of activated and thereby infectable lympho-
cytes is only a minor fraction of the whole population, this
second activity of Tat would provide a clever way to pre-
pare the T-cells for ef¢cient infection by the virus [13]. A
simian anti-Tat vaccine has very recently been reported to
work through inhibition of pathways presumably involving
a role of free Tat [13]. Accordingly, the Tat-interacting
stilbene compound described here could also have a favor-
able, inhibitory impact on these unwanted other activities
of Tat. This way, the compound class may function as
potent ‘double-hitting’ Tat antagonist, and those properties
could undoubtedly make a great impact on novel anti-HIV
therapy concepts.
Our observation of a very favorable cytotoxicity pro¢le (up
to mM concentrations) correlates well with the absence of
toxic effects of sulfonated diaminostilbene derivatives in
vertebrates [14].
Signi¢cance
For DNA- or RNA-binding drugs (kanamycin, adriamycin,
cis-Pt, bleomycin, etc.), the therapeutic window is usually
very narrow with high cytotoxicity, inherent to their mech-
anism of action, namely targeting genetic material. In turn,
Figure 6. (a) Three-dimensional view of
the major groove of bound TAR RNA
(coordinates from [7]). Atomic groups
critical for Tat-binding [9,10] are
highlighted. (b) Energy-minimized
conformation of CGA137053.
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the fact that the sulfonated stilbene compounds, described
here, indeed bind to the protein partner (Tat) of a protein/
nucleic acid complex may explain their surprisingly low
toxicity in cellular systems. The presented pro¢le of a
‘lead compound’ could serve as a starting point for further
synthetic optimization by medicinal chemistry. As more
disease-associated processes involving protein/nucleic acid
interactions are emerging, new concepts as the one de-
scribed above could open new drug strategies with impli-
cations far beyond anti-HIV therapies. Additional studies
will be necessary to further precise the interaction of the
identi¢ed compound class with Tat protein.
Materials and methods
Synthetic TAR sequences
TAR duplex was prepared by annealing the two synthetic oligoribonu-
cleotides: T-14 (5P-GCUGCUCUCUGGCU-3P) and T-17 (5P-AGCCA-
GAUUUGAGCAGC-3P) (Genset, Paris, France). The crude oligoribonu-
cleotides were puri¢ed on 20% polyacrylamide gels containing 8 M urea.
The 14-mer strand of the synthetic duplex TAR RNA was labelled with
T4 polynucleotide kinase using [Q-32P]ATP and annealed in the pres-
ence of 1.5 equivalents of the unlabelled 17-mer by heating the mixture
to 90³C for 3 min, followed by slow cooling to 0³C with a rate of 1³C per
min.
For experiments on the dynamics of binding, full-length TAR RNA (60
nucleotides) was obtained from in vitro transcription as follows. Syn-
thetic oligonucleotides corresponding to the wild-type TAR sequences
were cloned between the HindIII and EcoRI sites of the pUC19 plasmid.
After digestion with EcoRI, the RNA was transcribed as a run-off product
of 60 nucleotides from the T3 RNA polymerase promoter. In each case,
the transcript included an additional G residue on the 3P-end derived
from the EcoRI cleavage site. Transcription reaction was performed in
buffer containing 40 mM Tris^HCl, pH 7.4, 25 mM NaCl, 16 mM MgCl2,
10 mM dithiothreitol (DTT) and 1 mM NTPs. The reaction was initiated
by addition of 10 Wg linearized plasmid DNA template and 40 U T3 RNA
polymerase and incubated for 2 h at 37³C. Nucleic acids were then
fractionated on a 10% (w/v) polyacrylamide gel containing 8 M urea in
TBE buffer (89 mM Tris^borate pH 8.3, 10 mM EDTA). After electro-
phoresis, the RNA was eluted in water for 18 h at 4³C and precipitated
with ethanol. The RNA was resuspended in water to give a 500 WM
stock solution (O260/phosphate = 10 688 M31 cm31). RNA was 3P-end-
labelled with [32P]cytidine biphosphate and T4 RNA ligase and then
repuri¢ed from a 10% denaturing acrylamide gel.
EMSA
Binding reactions (25 Wl) contained 500 fmol (10 000 cpm) of the la-
belled duplex TAR RNA, 20 nM of recombinant Tat protein (Actigen,
Cambridge, UK) and varying concentrations of test compound in TK
buffer (20 mM Tris^HCl, pH 8.0, 50 mM KCl) with 10 mM DTT, 0.1%
Triton X-100. Order of addition and incubation conditions are described
within the Results. The binding reactions were analyzed by electropho-
resis on 8% non-denaturing polyacrylamide gels as described [15]. Fol-
lowing electrophoresis, the gels were either dried and exposed on X-ray
¢lm at 370³C for 16 h, or analyzed on a Phosphorimager (Molecular
Dynamics).
Fusion-induced gene stimulation (FIGS)
Coculture. The HeLa CD4 cell line SX22-1 (carrying a lacZ gene under
the control of the HIV-1 LTR) was cocultivated with the stably HIV-1-
infected lymphocyte line Hut/4-3 at a ratio of 3:1 [5]. After overnight
incubation, which permits syncytium formation and L-Gal synthesis,
the cells were washed once with phosphate-buffered saline (PBS),
¢xed with glutaraldehyde/formaldehyde (0.1%/0.7%) in PBS for 5 min
and stained for cell-associated L-Gal by using X-Gal as substrate. For
photometric quanti¢cation, the ¢xed cultures were subsequently incu-
bated with ONPG as L-Gal substrate, which is enzymatically converted
to the chromophoric ONP and absorption was measured at 405 nm.
Transfection FIGS. Alternatively, seeded SX22-1 cells were transfected
on the day following compound addition with plasmid DNA of either the
complete, infectious HIV-1 clone pNL4-3, or with the deletion construct
pTat/Rev (described in Klimkait et al. [5]). The latter, non-infectious
plasmid contains deletions of gag between a unique SpeI site (1507)
and EcoRI (5741), and of env between KpnI (6344) and HindIII (8131),
but preserves the splice sites for the tat and rev genes. Amounts of 1.2
Wg were transfected using the Fugene (Boehringer Mannheim, Ger-
many) or Transfast protocol (Promega, Madison, WI, USA). Two days
after transfection, cells were ¢xed and assayed.
Infection of primary cells
Lymphocytes [16] were cultured in RPMI 1640 medium containing 10%
fetal bovine serum; cells were activated for 2 days with 0.25 Wg/ml PHA
(Wellcome diagnostics, Temple Hill, Dartford, UK). After infection by
HIV-1, the cells were resuspended in complete medium, supplemented
with recombinant human interleukin 2 (Genzyme, Cambridge, MA, USA)
at 100 U/ml and plated at a density of 9U104 cells per well in U-bottom
96-well plates. Two-thirds of the culture medium was replaced by fresh
medium every 3 days. Virus production was evaluated by determining
RT activity in cell-free culture supernatants [17].
Tat induction of CXCR4 expression
Two micrograms of total RNA isolated from peripheral leukocytes from
healthy human donors by using Trizol reagent (Gibco BRL, Paisley, UK)
was primed with oligo dT and reverse transcribed into cDNA in a 20 Wl
reaction mixture containing Moloney murine leukemia virus RT (`super-
script'-RT; Gibco BRL). One microliter of the cDNA reaction mixture was
subjected to PCR ampli¢cation using `Hotstar' Taq DNA polymerase
(Qiagen, Hilden, Germany) in a thermocycler PE 9700 (PE/Biosystems,
Rotkreuz, Switzerland). A 15 min hot start activation of the enzyme was
followed by 30 cycles with denaturing at 95³C for 60 s, annealing at
60³C for 40 s and extension at 72³C for 90 s, followed by a ¢nal ex-
tension at 72³C for 5 min. The following primers were used 5P-GTTAC-
CATGGAGGGGATCAG-3P and 5P-CAGATGAATGTCCACCTCGC-3P.
Molecular modeling
Coordinates for the structure of arginine-bound TAR RNA [8] were ob-
tained from the Brookhaven protein data bank (pdb code = 1ARJ). Monte
Carlo conformational search was performed on CGA137053 (2000
structures) using the Macromodel version 6.0 software package (Colum-
bia University, New York, NY, USA) on an Octane workstation (Silicon
Graphics, Mountain View, CA, USA). Graphics and measurements were
done using the Insight II software (Molecular Simulation Inc., San Diego,
CA, USA).
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